Dine Brands International Announces 2025 Restaurant Development Plans
The company expands their dual-branded Applebee’s l IHOP restaurant concept into Costa Rica and opens first non-traditional restaurant in Mexico
Dine Brands International – an affiliate of Dine Brands Global, Inc., the parent company of Applebee’s Neighborhood Grill + Bar®, IHOP®, and Fuzzy’sTaco Shop® restaurants – is set to expand its dual-branded Applebee’s and IHOP concept in 2025. This expansion includes entering the Costa Rican market with franchisee BLT UK Holdings Limited, and opening the first non-traditional restaurants in Mexico with franchisees Grupo Shogua and ATH Group.
The dual-branded format, combining Applebee’s and IHOP under one roof, has been a key part of Dine Brands’ international growth strategy. Currently, there are 18 dual-branded locations across seven markets: Mexico, Canada, UAE, Kuwait, Saudi Arabia, Honduras, and Peru. In 2025, the company aims to open 13 additional dual-branded restaurants in new international markets and complete 10 dual conversions, bringing the total number of dual-branded restaurants to 41. Franchisee BLT UK Holdings Limited opened the first dual-branded restaurant in Honduras in 2024 and plans to open a second location this year. They will also be opening the first dual-branded restaurant in Costa Rica this Summer in San Jose.
Building on the success of 2024, where Dine Brands International and its franchisees opened 36 new restaurants and entered new markets like Honduras, the 2025 expansion will focus on both traditional and non-traditional growth opportunities. In addition to franchisee ATH Group opening the first non-traditional dual-branded restaurant at the Parador Pedro Escobedo travel center in Mexico, franchisee Grupo Shogua will also open an IHOP restaurant at Felipe Ángeles International Airport (AIFA) in Mexico City.
“I am incredibly proud of the progress we are making to expand and grow with new and existing franchisees around the world,” said Scott Gladstone, President, International and Corporate Development at Dine Brands Global. “Our expansion plans create opportunities to adapt to local customs, tastes, and traditions, as well as new formats and varying footprints. We are committed to creating compelling and profitable opportunities for franchisees and the company, and new and unique experiences for our guests.”
Dine Brands is seeking qualified Master Developers in selected territories in Mexico (Baja California Sur, Sonora, Sinaloa, Aguascalientes, Zacatecas, Coahuila, Durango, Nayarit, Colima, Hidalgo, Guerrero, Oaxaca), selected territories in Canada, as well as Master Franchisees/Master Developers in selected markets in Europe and Asia, including South Korea, Japan, and Spain. For franchising opportunities, please visit https://franchise.ihop.com/en/applebees-co-branded-franchising.
About Dine Brands Global, Inc.
Based in Pasadena, California, Dine Brands Global, Inc. (NYSE: DIN), through its subsidiaries and franchisees, supports and operates restaurants under the Applebee’s Neighborhood Grill + Bar®, IHOP®, and Fuzzy’s Taco Shop® brands. As of December 31, 2024, these three brands consisted of over 3,500 restaurants across 19 international markets. Dine Brands is one of the largest full-service restaurant companies in the world and in 2022 expanded into the Fast Casual segment. For more information on Dine Brands, visit the Company’s website located at www.dinebrands.com.
BR-INTL
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313616481/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release
Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom